Therapeutics News and Research

RSS

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

UMass Medical School (UMMS) recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

13 Feb 2014

Experts to meet in Biovision's annual forum to discuss effects of disruptive innovation in healthcare

Biovision, the annual forum devoted to future-oriented research in life sciences, is launching this years’ registration campaign and its call for applications for innovative projects and companies. This year’s event will take place in Lyon, France, on June 5 and 6, 2014.

12 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

A new study led by University of Kentucky Markey Cancer Center researcher Peter Zhou shows that targeting Twist, a nuclear protein that is an accelerant of the epithelial-mesenchymal transition (EMT) program in human cells, may provide an effective approach for treating triple-negative breast cancer.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

New receptors act as biological postal code for treating cancer

Scientists have discovered that a polymer can provide a key to get into tumors: Prof. Prasad Shastri, Director of the Institute of Macromolecular Chemistry and core member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg, and graduate students Julia Voigt and Jon Christensen have developed a new paradigm to home nanoparticles, containers that measure a few 100 nanometers in size, to endothelial cells.

11 Feb 2014

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

10 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

10 Feb 2014

Researchers identify protein that regulates how genetic information transcribed from DNA to mRNA

Molecular biologists from Indiana University are part of a team that has identified a protein that regulates the information present in a large number of messenger ribonucleic acid molecules that are important for carrying genetic information from DNA to protein synthesis.

7 Feb 2014

Proprietary supplement improves cognitive processing speed of older adults

Declines in the underlying brain skills needed to think, remember and learn are normal in aging. In fact, this cognitive decline is a fact of life for most older Americans.

7 Feb 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

6 Feb 2014

Blood disorder medicines could be used for treating stomach and bowel cancer

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.

5 Feb 2014

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

4 Feb 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

Therapeutics News and Research

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

Experts to meet in Biovision's annual forum to discuss effects of disruptive innovation in healthcare

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

IMF announces approval of POMALYST medication in Canada for patients with myeloma

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

New receptors act as biological postal code for treating cancer

Combination of infused vitamin C and conventional chemotherapy drugs stops ovarian cancer

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Scientists develop new approach to design drugs from genome sequence

Researchers identify protein that regulates how genetic information transcribed from DNA to mRNA

Proprietary supplement improves cognitive processing speed of older adults

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Blood disorder medicines could be used for treating stomach and bowel cancer

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News